<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article article-type="research-article" dtd-version="2.3" xml:lang="EN" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">Front. Pharmacol.</journal-id>
<journal-title>Frontiers in Pharmacology</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Front. Pharmacol.</abbrev-journal-title>
<issn pub-type="epub">1663-9812</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="publisher-id">1428572</article-id>
<article-id pub-id-type="doi">10.3389/fphar.2024.1428572</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Pharmacology</subject>
<subj-group>
<subject>Original Research</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Exploration of the mechanism of Taohong Siwu Decoction for the treatment of ischemic stroke based on CCL2/CCR2 axis</article-title>
<alt-title alt-title-type="left-running-head">Li et al.</alt-title>
<alt-title alt-title-type="right-running-head">
<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3389/fphar.2024.1428572">10.3389/fphar.2024.1428572</ext-link>
</alt-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" equal-contrib="yes">
<name>
<surname>Li</surname>
<given-names>Jingjing</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<xref ref-type="author-notes" rid="fn001">
<sup>&#x2020;</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/2636687/overview"/>
<role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/>
<role content-type="https://credit.niso.org/contributor-roles/investigation/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/>
</contrib>
<contrib contrib-type="author" equal-contrib="yes">
<name>
<surname>Zhang</surname>
<given-names>Lijuan</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<xref ref-type="author-notes" rid="fn001">
<sup>&#x2020;</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/1917203/overview"/>
<role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/>
<role content-type="https://credit.niso.org/contributor-roles/investigation/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Xue</surname>
<given-names>Sujun</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/1917197/overview"/>
<role content-type="https://credit.niso.org/contributor-roles/data-curation/"/>
<role content-type="https://credit.niso.org/contributor-roles/Writing - review &#x26; editing/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Yu</surname>
<given-names>Chao</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/1917193/overview"/>
<role content-type="https://credit.niso.org/contributor-roles/formal-analysis/"/>
<role content-type="https://credit.niso.org/contributor-roles/investigation/"/>
<role content-type="https://credit.niso.org/contributor-roles/Writing - review &#x26; editing/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Li</surname>
<given-names>Yumeng</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/2646956/overview"/>
<role content-type="https://credit.niso.org/contributor-roles/formal-analysis/"/>
<role content-type="https://credit.niso.org/contributor-roles/Writing - review &#x26; editing/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Li</surname>
<given-names>Shuangping</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<role content-type="https://credit.niso.org/contributor-roles/investigation/"/>
<role content-type="https://credit.niso.org/contributor-roles/resources/"/>
<role content-type="https://credit.niso.org/contributor-roles/Writing - review &#x26; editing/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Ye</surname>
<given-names>Qingping</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<role content-type="https://credit.niso.org/contributor-roles/investigation/"/>
<role content-type="https://credit.niso.org/contributor-roles/resources/"/>
<role content-type="https://credit.niso.org/contributor-roles/Writing - review &#x26; editing/"/>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Duan</surname>
<given-names>Xianchun</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref>
<xref ref-type="corresp" rid="c001">&#x2a;</xref>
<uri xlink:href="https://loop.frontiersin.org/people/843243/overview"/>
<role content-type="https://credit.niso.org/contributor-roles/funding-acquisition/"/>
<role content-type="https://credit.niso.org/contributor-roles/supervision/"/>
<role content-type="https://credit.niso.org/contributor-roles/Writing - review &#x26; editing/"/>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Peng</surname>
<given-names>Daiyin</given-names>
</name>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref>
<xref ref-type="corresp" rid="c001">&#x2a;</xref>
<uri xlink:href="https://loop.frontiersin.org/people/665203/overview"/>
<role content-type="https://credit.niso.org/contributor-roles/supervision/"/>
<role content-type="https://credit.niso.org/contributor-roles/Writing - review &#x26; editing/"/>
</contrib>
</contrib-group>
<aff id="aff1">
<sup>1</sup>
<institution>Department of Pharmacy</institution>, <institution>The First Affiliated Hospital of Anhui University of Chinese Medicine</institution>, <addr-line>Hefei</addr-line>, <country>China</country>
</aff>
<aff id="aff2">
<sup>2</sup>
<institution>School of Pharmacy</institution>, <institution>Anhui University of Chinese Medicine</institution>, <addr-line>Hefei</addr-line>, <country>China</country>
</aff>
<aff id="aff3">
<sup>3</sup>
<institution>Key Laboratory of Chinese Medicinal Formula Research</institution>, <institution>Anhui University of Chinese Medicine</institution>, <addr-line>Hefei</addr-line>, <country>China</country>
</aff>
<author-notes>
<fn fn-type="edited-by">
<p>
<bold>Edited by:</bold> <ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/158264/overview">Jose Javier Miguel-Hidalgo</ext-link>, University of Mississippi Medical Center, United States</p>
</fn>
<fn fn-type="edited-by">
<p>
<bold>Reviewed by:</bold> <ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/2036572/overview">Ahmed Alhusban</ext-link>, University of Sharjah, United Arab Emirates</p>
<p>
<ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/1529193/overview">Faqiang Zhang</ext-link>, Tongji University, China</p>
<p>
<ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/1654795/overview">Zhehao Hu</ext-link>, University of Southern California, United States</p>
</fn>
<corresp id="c001">&#x2a;Correspondence: Xianchun Duan, <email>duanxc@ahtcm.edu.cn</email>; Daiyin Peng, <email>pengdaiyin@163.com</email>
</corresp>
<fn fn-type="equal" id="fn001">
<label>
<sup>&#x2020;</sup>
</label>
<p>These authors have contributed equally to this work and share first authorship</p>
</fn>
</author-notes>
<pub-date pub-type="epub">
<day>29</day>
<month>08</month>
<year>2024</year>
</pub-date>
<pub-date pub-type="collection">
<year>2024</year>
</pub-date>
<volume>15</volume>
<elocation-id>1428572</elocation-id>
<history>
<date date-type="received">
<day>06</day>
<month>05</month>
<year>2024</year>
</date>
<date date-type="accepted">
<day>16</day>
<month>08</month>
<year>2024</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#xa9; 2024 Li, Zhang, Xue, Yu, Li, Li, Ye, Duan and Peng.</copyright-statement>
<copyright-year>2024</copyright-year>
<copyright-holder>Li, Zhang, Xue, Yu, Li, Li, Ye, Duan and Peng</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/">
<p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</p>
</license>
</permissions>
<abstract>
<sec>
<title>Background and aims</title>
<p>Taohong Siwu Decoction (THSWD) is a traditional Chinese herbal prescription that is effective for ischemic stroke, Whether THSWD regulates the CCL2/CCR2 axis and thus reduces the inflammatory response induced by ischemic stroke is not known. The aim of this study was to elucidate the mechanism of action of THSWD in the treatment of ischemic stroke using bioinformatics combined with <italic>in vitro</italic> and <italic>in vivo</italic> experiments.</p>
</sec>
<sec>
<title>Methods</title>
<p>R language was used to analyze middle cerebral artery occlusion/reperfusion (MCAO/R) rat transcriptome data and to identify differential gene expression following THSWD treatment. Gene set enrichment analysis (GSEA) was used to analyze the gene set enrichment pathway of MCAO/R rats treated with THSWD. PPI networks screened key targets. The Human Brain Microvascular Endothelial Cells (HBMEC) Oxygen Glucose Deprivation/Reoxygenation (OGD/R) model and SD rat models of MCAO/R were established. FITC-dextran, immunofluorescence, flow cytometry, ELISA, immunohistochemistry, Western blotting, and RT-qPCR were performed to identify potential treatment targets.</p>
</sec>
<sec>
<title>Results</title>
<p>A total of 515 differentially expressed genes of THSWD in MCAO/R rats were screened and 92 differentially expressed genes of THSWD potentially involved in stroke intervention were identified, including Cd68, Ccl2, and other key genes. <italic>In vitro</italic>, THSWD reversed the increase in permeability of HBMEC cells and M1/M2 polarization of macrophages induced by CCL2/CCR2 axis agonists. <italic>In vivo</italic>, THSWD improved nerve function injury and blood-brain barrier injury in MCAO/R rats. Further, THSWD inhibited the infiltration and polarization of macrophages, reduced the expression of IL-6, TNF-&#x3b1;, and MMP-9, and increased the expression of IL-4, while reducing the gene and protein expression of CCL2 and CCR2.</p>
</sec>
<sec>
<title>Conclusion</title>
<p>THSWD may play a protective role in ischemic stroke by inhibiting the CCL2/CCR2 axis, reducing the infiltration of macrophages, and promoting the polarization of M2 macrophages, thereby reducing inflammatory damage, and protecting injury to the blood-brain barrier.</p>
</sec>
</abstract>
<kwd-group>
<kwd>Taohong Siwu Decoction (THSWD)</kwd>
<kwd>ischemic stroke</kwd>
<kwd>bioinformatics</kwd>
<kwd>CCL2/CCR2 axis</kwd>
<kwd>immune inflammation</kwd>
</kwd-group>
<custom-meta-wrap>
<custom-meta>
<meta-name>section-at-acceptance</meta-name>
<meta-value>Neuropharmacology</meta-value>
</custom-meta>
</custom-meta-wrap>
</article-meta>
</front>
<body>
<sec id="s1">
<title>1 Introduction</title>
<p>The burden of ischemic stroke on the lives of individuals is increasing worldwide, and the situation is particularly serious in China, which is reported to account for nearly one-third of the global total of stroke-related deaths (<xref ref-type="bibr" rid="B25">Wu et al., 2022</xref>). Ischemic stroke is characterized by an abrupt interruption of blood flow to a particular brain region of the brain, leading to inadequate oxygen and glucose provided to the ischemic tissue. Timely blood reperfusion can save dying tissue but may also lead to secondary damage to infarct tissue and to the blood-brain barrier (BBB) (<xref ref-type="bibr" rid="B26">Xie et al., 2022</xref>). Therefore, it is meaningful to investigate the mechanism of ischemic stroke and its treatment.</p>
<p>CCL2, or monocyte chemoattractant protein-1 (MCP-1), was the first human monocyte chemokine to be discovered, and its biological function is mediated by binding to its cognate receptor, the CC motif chemokine receptor 2 (CCR2) (<xref ref-type="bibr" rid="B6">Bianconi et al., 2018</xref>). CCL2 binds to CCR2 to mediate monocyte migration into the brain (<xref ref-type="bibr" rid="B3">Bai et al., 2023a</xref>). Monocytes differentiate into macrophages or dendritic cells (DC) according to the local tissue environment. M1 macrophages are pro-inflammatory at the site of brain injury, producing cytokines such as interleukin (IL)-6 and tumor necrosis factor (TNF)-&#x3b1; (<xref ref-type="bibr" rid="B4">Bai et al., 2023b</xref>). The BBB is connected by tight junction proteins on the surface of endothelial cells, and BBB damage is related to the influx of inflammatory cells (<xref ref-type="bibr" rid="B15">Salvador et al., 2015</xref>). Early research has shown that CCL2 in various pathological conditions mediated by BBB damage (<xref ref-type="bibr" rid="B10">Errede et al., 2022</xref>), with the increasing of BBB permeability, infiltrating chemical mediators and inflammatory cells (such as macrophages) cause inflammation, which further enhances BBB permeability. Additionally, after ischemic stroke, functional damage to neurons is aggravated, resulting in neuronal apoptosis, during which a large number of microglia/macrophages are activated, which, in turn, produces pro-inflammatory cytokines, further aggravating neuronal apoptosis during ischemic stroke (<xref ref-type="bibr" rid="B16">Shao et al., 2022</xref>). Inhibiting macrophage infiltration and maintaining BBB integrity have been confirmed in studies to be mutually reinforcing (<xref ref-type="bibr" rid="B7">Cao et al., 2021</xref>). Therefore, down-regulating chemokine expression and preventing infiltration of inflammatory cells (such as macrophages) is likely to be an effective way to reduce BBB permeability and protect the brain from injury (<xref ref-type="bibr" rid="B14">Payen et al., 2003</xref>).</p>
<p>Taohong Siwu Decoction (THSWD) is composed of Tao-ren, Hong-hua, Dang-gui, Chuan-xiong, and Bai-shao in certain proportions. This prescription first appeared in &#x201c;Yi Zong Jin Jian&#x201d; written by Wu Qian during the Qing Dynasty and is a classic formula for activating blood circulation and removing blood stasis. Clinically, it has been used for the treatment and prevention of cerebrovascular diseases (<xref ref-type="bibr" rid="B9">Duan et al., 2018</xref>). Previous studies have shown that THSWD is neuroprotective in brain injury models and can reduce ischemic stroke injury by inhibiting cell necrosis, neuroinflammation, and cell pyrodeath (<xref ref-type="bibr" rid="B22">Wang et al., 2020</xref>; <xref ref-type="bibr" rid="B23">Wang et al., 2021</xref>); THSWD can also treat ischemic stroke by improving vascular structure and promoting angiogenesis (<xref ref-type="bibr" rid="B21">Tang et al., 2024</xref>). However, few studies have evaluated the transcriptomics of THSWD therapy for ischemic stroke based on bioinformatic methods. In this study, we investigated the immunoinflammatory-related mechanisms of THSWD for ischemic stroke based on bioinformatics methods and performed <italic>in vitro</italic> and <italic>in vivo</italic> experiments to validate and investigate the role played by CCL2/CCR2 in the therapeutic process of THSWD for ischemic stroke. To complement the pharmacological effects of THSWD in the treatment of ischemic stroke. Nimodipine has neuroprotective effects against ischemic stroke and has been proven to reduce the area of brain tissue damage after cerebral infarction, as well as improve neurological functional impairment following cerebral ischemia (<xref ref-type="bibr" rid="B20">Sun et al., 2023</xref>). Therefore, in this study, we used nimodipine as a positive control.</p>
</sec>
<sec sec-type="materials|methods" id="s2">
<title>2 Materials and methods</title>
<sec id="s2-1">
<title>2.1 Medicinal materials and reagents</title>
<p>Tao-ren (NO: 20230818), Hong-hua (NO: 2307273), Dang-gui (NO: 2230301), Chuan-xiong (NO: 2307091), Bai-shao (NO: 2307200022), and Shu-di (NO: 2307173) medicinal materials (ratio: 3:2:4:3:3:2) were all purchased from the First Affiliated Hospital of Anhui University of Chinese Medicine. For the preparation of THSWD water extract, the herbs were prepared according to the THSWD ratios, extracted with water, and then concentrated using a rotary evaporator to a concentrate with a drug content of 1.8&#xa0;g/mL.</p>
<p>Nimodipine (cat.no. 210507) was purchased from Yabo Pharmaceutical Group Co., LTD., TRIzol extraction reagent (cat.no. 15596026) was purchased from Thermo Fisher Scientific, mirVana&#x2122; miRNA isolation kit (cat.no. AM1561) from Ambion, CCK8 test kit (cat.no. CR2112050) from Servicebio, anti-Human CD86 (B7-2) (cat.no. A10944), anti-Human/Mouse CD11b (cat.no. A11042), were both purchased from MultiSciences, APC anti-Human CD206 (LW1218) was purchased from Elabscience, human TNF-&#x3b1; (July 2023), Human matrix metalloproteinase 9 (MMP-9) (July 2023), human IL-6 (July 2023), human IL-4 (July 2023), rat TNF-&#x3b1; (May 2023), rat MMP-9 (May 2023), rat IL-6 (May 2023), rat IL-4 (May 2023) were purchased from Quanzhou Ruixin Biotechnology Co., Ltd., claudin-5 (cat.no. 23o5501), CCL2 (cat.no. 60d7593), and CCR2 (cat.no. 60e2906) were purchased from Affinity, DAPI (cat.no. 22334227) from Beyotime, FITC-Dextran (cat.no. 178439) from MCE, &#x3b2;-actin (cat.no. 19AW0505), goat anti-mouse IgG (cat.no. 142637), and goat anti-rabbit IgG (cat.no. 139931) were purchased from Zs-BIO.</p>
</sec>
<sec id="s2-2">
<title>2.2 Animals and model preparation</title>
<p>Male SPF grade SD rats (150&#x2013;180&#xa0;g) were purchased from Liaoning Changsheng Biotechnology Co., Ltd. The animal experiments were approved by the Experimental Animal Ethics Committee of the Anhui University of Chinese Medicine (Permit Number: LLSC20160036).</p>
<p>Establishment of the MCAO/R model was described previously (<xref ref-type="bibr" rid="B12">Ji et al., 2022</xref>). Briefly, the ophthalmic scissors made a 1.0-cm incision in the middle of the neck. The proximal end of the right common carotid artery (CCA) and the external carotid artery (ECA) were ligated with a 5-cm suture. After closing the distal end of the internal carotid artery (ICA) with an artery clamp, a nylon wire was inserted into the intersection of ECA and ICA to an inward depth of (18.5 &#xb1; 0.5)&#xa0;mm, obstruction of the middle cerebral artery was thus achieved and the cord was removed after 2&#xa0;h of ischemia, and the MCAO/R model was created. In the sham group, only ECA and ICA were ligated, and no other special treatment was performed.</p>
</sec>
<sec id="s2-3">
<title>2.3 Bioinformatics approaches to study potential immunoinflammation-related targets of THSWD for the treatment of ischemic stroke</title>
<sec id="s2-3-1">
<title>2.3.1 Differential expression gene screening and GSEA analysis</title>
<p>RNA sequencing data was obtained from on a preliminary high-throughput sequencing study (<xref ref-type="bibr" rid="B9">Duan et al., 2018</xref>), Using EdgeR in R 4.2.1 compared DEG expression in the MCAO/R and sham groups and between the THSWD and MCAO/R groups, respectively. <italic>p</italic> &#x3c; 0.05 and &#x7c;logFC&#x7c; &#x3e; 1 were defined as significant difference criteria. Venny 2.1.0 (<ext-link ext-link-type="uri" xlink:href="https://bioinfogp.cnb.csic.es/tools/venny/">https://bioinfogp.cnb.csic.es/tools/venny/</ext-link>) was used to screen DEGs [MCAO/R vs sham (MVSC) and THSWD vs MCAO/R (DVSM)].</p>
<p>Transcriptome data was collated and analyzed using gene set enrichment analysis (GSEA) and enrichplot with R packages (clusterProfiler, org. Rn.eg.dbde, Enrichplot, pathview, dplyr, reshape2, ggplot2, and ggridges), where pvalueCutoff &#x3d; 0.05 were used for the analyses. When both the <italic>P</italic>-value and the FDR were &#x3c;0.05, it indicated a significant gene set enrichment.</p>
</sec>
<sec id="s2-3-2">
<title>2.3.2 Immunoinflammation-related gene screening and enrichment analysis</title>
<p>R4.2.1 was used to screen immunoinflammatory genes in the GO and KEGG databases. After dereprocessing, the two groups of immunoinflammatory genes were mixed with DVSM and MVSC to obtain immunoinflammatory-related differential genes for the THSWD intervention in ischemic stroke. R packages (ClusterProfiler, BiocManager, AnnotationHub, AnnotationDbi, and ggplot2) were applied to GO and KEGG analysis to identify immunoinflammatory-related differential gene expression following THSWD treatment of ischemic stroke with pvalueCutoff &#x3d; 0.05 and qvalueCutoff &#x3d; 0.05.</p>
</sec>
<sec id="s2-3-3">
<title>2.3.3 Protein-protein interaction network construction and key gene screening</title>
<p>The protein-protein interaction (PPI) network map of genes related to immune inflammation was created using the String database (<ext-link ext-link-type="uri" xlink:href="https://cn.string-db.org/">https://cn.string-db.org/</ext-link>) and imported into Cytoscape 3.9.1 for the visualization of the selected genes. The CytoHubba analysis module network was also used and the MCC algorithm was selected to identify genes with the highest score as key genes.</p>
</sec>
</sec>
<sec id="s2-4">
<title>2.4 Immunoinflammatory protective effect of THSWD on the OGD/R model of human brain microvascular endothelial cells</title>
<sec id="s2-4-1">
<title>2.4.1 Preparation of THSWD drug-containing serum</title>
<p>Twenty-four healthy SD rats, 10 rats were grafted with THSWD (18&#xa0;g/kg) once a day in the morning and once a night for 3 consecutive days. The remaining rats received an equal amount of saline. One hour after the last gavage, 3% pentobarbital sodium was injected intraperitoneally, blood was taken from the abdominal aorta, left for rest, serum was taken after centrifugation, bacteria were removed with a 0.22&#xa0;&#x3bc;m filter, and then stored at &#x2212;80&#xb0;C after subpacking.</p>
</sec>
<sec id="s2-4-2">
<title>2.4.2 Grouping and intervention methods</title>
<p>Human Brain Microvascular Endothelial Cells (HBMEC) were randomly divided into 6 groups: control, OGD/R, OGD/R &#x2b; CCL2/CCR2 axis agonist (Agonist), OGD/R &#x2b; CCL2/CCR2 axis inhibitor (Inhibitor), OGD/R &#x2b; THSWD (THSWD), OGD/R &#x2b; CCL2/CCR2 axis agonist &#x2b; THSWD (THSWD &#x2b; Agonist) groups. Molding method: HBMEC cells were seeded in the lower chamber of the 6-well plate and THP-1 cells were seeded in the coculture chamber. After 48&#xa0;h of coculture with PMA100&#xa0;ng/mL, HBMEC cells, except for the control group, were rinsed with PBS, then glucose-free DMEM medium was added to the anoxic incubator for 2&#xa0;h, and the medium was changed into a complete medium and returned to the original incubator for 24&#xa0;h. For the Agonist group: the final concentration of CCL2 was 200&#xa0;ng/mL and treated duration was 24&#xa0;h. For the Inhibitor group, the CCR2 inhibitor RS102896 was added to a final concentration 10&#xa0;&#x3bc;M and cells were treated for 24&#xa0;h. For the THSWD group, 10% drug-containing serum was added and cells were treated for 48&#xa0;h. For the THSWD &#x2b; Agonist group, drug-containing serum was added first, and agonist was added 24&#xa0;h later and treatment continued for 24&#xa0;h. For the control group and the OGD/R group there was no other processing.</p>
</sec>
<sec id="s2-4-3">
<title>2.4.3 Cell viability was detected by CCK-8</title>
<p>According to the manufacturer&#x2019;s instructions for the CCK-8 (CellCountingKit-8) test kit, cells were inoculated in 96-well culture plates at a density of 1&#xd7;10<sup>5</sup>, with 100&#xa0;&#x3bc;L per well and 6 multiple wells per set. The inoculated cell culture plates were placed in the incubator overnight for culture, and then the cells were molded and dosed, 10&#xa0;&#x3bc;L CCK8 was added to each well, and the culture was continued for 1&#xa0;h. The light absorption values of each hole were measured at OD450&#xa0;nm in the ELISA, and blank holes were set.</p>
</sec>
<sec id="s2-4-4">
<title>2.4.4 FITC-glucan was used to measure endothelial cell permeability</title>
<p>HBMEC cells were inoculated in the upper inner compartment of the Transwell compartment and the lower compartment contained THP-1 cells. After cell growth and fusion, serum-free medium was cultured overnight to synchronize the cells. After the cells were molded and dosed, 1&#xa0;mg/mL of FITC-Dextran was added and cells were placed in the incubator for 5&#xa0;h. Samples of 100&#xa0;&#x3bc;L were taken from the top chamber and the bottom chamber of each bilayer chamber, and the fluorescence intensity of the samples was detected by a fluorescence enzyme spectrometer. The excitation wavelength was 485&#xa0;nm and the emission wavelength was 595&#xa0;nm. The volume of fluid in the bottom chamber was also measured.</p>
</sec>
<sec id="s2-4-5">
<title>2.4.5 Claudin-5 protein expression was determined by immunofluorescence</title>
<p>The cocultured cells were inoculated in the tablet at an appropriate density. After molding, the culture medium was discarded and cleaned with PBS 3 times and 4% paraformaldehyde was added to fix cells for 20&#xa0;min, and then washed with PBS 3 times. A PBS solution containing 0.25%TritonX-100 was added and incubated for 10&#xa0;min. PBS was cleaned three times. Next, a 4% BSA solution was added to seal cells for 30&#xa0;min. The BSA solution was then removed and the primary antibody was added, incubated at 4&#xb0;C overnight, washed with PBS, before the secondary antibody was added, and incubated for 3&#xa0;h and washed 3 times with PBS. The slides were sealed with antifluorescence quenched tablets containing DAPI and observed and photographed by a high-resolution fluorescence microscope.</p>
</sec>
<sec id="s2-4-6">
<title>2.4.6 Macrophage polarization was detected by flow cytometry</title>
<p>The treated cells were collected, mixed with anti-CD11 and CD86 antibodies, and incubated at room temperature for 15&#xa0;min away from light. The cells were permeated according to instructions, the membrane was broken, the anti-CD206 antibody was added and incubated at room temperature for 15&#xa0;min away from light. After washing, cells were resuspended with an appropriate amount of PBS containing 5% FBS and then filtered by 200&#xa0;mesh.</p>
</sec>
<sec id="s2-4-7">
<title>2.4.7 ELISA was used to detect IL-4, IL-6, TNF-&#x3b1; and MMP-9</title>
<p>The cocultured cells were lysed and centrifuged, the supernatant was retrieved, and the contents of the related indexes were determined according to the requirements of the kit.</p>
</sec>
<sec id="s2-4-8">
<title>2.4.8 Western blotting was used to detect the expression of the CCL2 and CCR2 protein</title>
<p>The collected and treated cells were added to the lysate and centrifuged at 12,000&#xa0;r/min for 15&#xa0;min, and the protein was quantified using the BCA method. Protein samples were transferred to the PVDF membrane after SDS-PAGE gel electrophoresis at room temperature for 2&#xa0;h. Next, membranes were incubated with the primary antibody CCL2 and CCR2 (1:1,000) and incubated at 4&#xb0;C overnight. The secondary antibody (1:10,000) was added, and incubated at room temperature for 2&#xa0;h. Membranes were washed with PBST three times, and the ECL developer was added to visualize protein bands. Imaging was captured and analyzed by ImageJ software.</p>
</sec>
<sec id="s2-4-9">
<title>2.4.9 RT-qPCR detected CCL2, CCR2 gene expression</title>
<p>The treated cells were collected, total RNA was extracted according to the instructions of the Trizol kit, and cDNA was synthesized by reverse transcription. The sequences of each quantitative PCR primer are shown in <xref ref-type="table" rid="T1">Table 1</xref>. The amplification mix volume was 20&#xa0;&#x3bc;L: 2&#xd7;SYBR Green qPCR Master Mix 10&#xa0;&#x3bc;L, forward Primer (10&#xa0;&#x3bc;M) 0.4&#xa0;&#x3bc;L, Reverse Primer (10&#xa0;&#x3bc;M) 0.4&#xa0;&#x3bc;L, cDNA 3&#xa0;&#x3bc;L, and RNase-free water 6.2&#xa0;&#x3bc;L. The reaction conditions were as follows: 95&#xb0;C 30&#xa0;s, 95&#xb0;C 15&#xa0;s, and 60&#xb0;C 30&#xa0;s for 40 cycles. After the amplification reaction, the relative expression level of mRNA in each group was compared using the 2<sup>&#x2212;&#x394;&#x394;Ct</sup> method.</p>
<table-wrap id="T1" position="float">
<label>TABLE 1</label>
<caption>
<p>Primer sequences.</p>
</caption>
<table>
<thead valign="top">
<tr>
<th align="center">Gene</th>
<th align="center">Amplicon Size (bp)</th>
<th align="center">Forward primer (5&#x27;&#x2192;3&#x2032;)</th>
<th align="center">Reverse primer (5&#x27;&#x2192;3&#x2032;)</th>
</tr>
</thead>
<tbody valign="top">
<tr>
<td align="center">Hu-&#x3b2;-actin</td>
<td align="center">96</td>
<td align="center">CCC&#x200b;TGG&#x200b;AGA&#x200b;AGA&#x200b;GCT&#x200b;ACG&#x200b;AG</td>
<td align="center">GGA&#x200b;AGG&#x200b;AAG&#x200b;GCT&#x200b;GGA&#x200b;AGA&#x200b;GT</td>
</tr>
<tr>
<td align="center">Hu-CCL2</td>
<td align="center">127</td>
<td align="center">CAG&#x200b;CAG&#x200b;CAA&#x200b;GTG&#x200b;TCC&#x200b;CAA&#x200b;AG</td>
<td align="center">CGG&#x200b;AGT&#x200b;TTG&#x200b;GGT&#x200b;TTG&#x200b;CTT&#x200b;GT</td>
</tr>
<tr>
<td align="center">Hu-CCR2</td>
<td align="center">110</td>
<td align="center">AGT&#x200b;CAA&#x200b;CTG&#x200b;GAC&#x200b;CAA&#x200b;GCC&#x200b;AC</td>
<td align="center">TGA&#x200b;AAA&#x200b;AGG&#x200b;CTT&#x200b;CTG&#x200b;AAC&#x200b;TTC&#x200b;TCC</td>
</tr>
</tbody>
</table>
</table-wrap>
</sec>
</sec>
<sec id="s2-5">
<title>2.5 Protective effect of THSWD on brain injury in MCAO/R model rats</title>
<sec id="s2-5-1">
<title>2.5.1 Grouping and administration</title>
<p>Rats with successful modeling were randomly divided into 6 groups with 18 rats in each group, which were treated as follows: H-THSWD (18&#xa0;g/kg), M-THSWD (9&#xa0;g/kg), L-THSWD (4.5&#xa0;g/kg), nimodipine (NMDP) (20&#xa0;mg/kg), sham, and MCAO/R groups, respectively. The drug treatment group was treated by gavage according to the proportion of body weight 2&#xa0;days after surgery, and the sham group and the MCAO/R group received the same amount of normal saline once a day for 7 consecutive days.</p>
</sec>
<sec id="s2-5-2">
<title>2.5.2 Berderson score</title>
<p>After 7&#xa0;days of administration, the neurological defects of the rats were scored, detailed scoring rules are shown in <xref ref-type="table" rid="T2">Table 2</xref>. Higher-scoring rats indicated more severe neurological deficits.</p>
<table-wrap id="T2" position="float">
<label>TABLE 2</label>
<caption>
<p>Neurological function score.</p>
</caption>
<table>
<thead valign="top">
<tr>
<th align="left">Score</th>
<th align="left">Symptoms seen in rats</th>
</tr>
</thead>
<tbody valign="top">
<tr>
<td align="left">0</td>
<td align="left">Moved normally</td>
</tr>
<tr>
<td align="left">1</td>
<td align="left">The left front paw could not be successfully extended</td>
</tr>
<tr>
<td align="left">2</td>
<td align="left">Turned to the left when crawling</td>
</tr>
<tr>
<td align="left">3</td>
<td align="left">The rat&#x2019;s body was skewed to the left when crawling</td>
</tr>
<tr>
<td align="left">4</td>
<td align="left">Unconscious, unable to crawl</td>
</tr>
</tbody>
</table>
</table-wrap>
</sec>
<sec id="s2-5-3">
<title>2.5.3 TTC staining was used to calculate the volume of cerebral infarction</title>
<p>One hour after the last administration, the rats were anesthetized, blood was collected from the abdominal aorta, followed by decapitation to harvest the brain, and frozen at &#x2212;20&#x00B0;C for about half an hour. Specimens were cut into five coronal sections with a thickness of approximately 2&#xa0;mm. The sections were then submerged in a 2% TTC solution, shielded from light by tinfoil, and incubated at 37&#xb0;C for 30&#xa0;min. Normal brain tissue was pink and the infarct area was white. After staining, tissue specimens were fixed in 4% paraformaldehyde, photographed, and recorded 24&#xa0;h later. ImageJ was used for analysis and the infarct volume was calculated according to the formula.<disp-formula id="equ1">
<mml:math id="m1">
<mml:mrow>
<mml:mtext>Corrected&#x2009;infarct&#x2009;volume&#x2009;</mml:mtext>
<mml:mrow>
<mml:mfenced open="(" close=")" separators="|">
<mml:mrow>
<mml:mo>%</mml:mo>
</mml:mrow>
</mml:mfenced>
</mml:mrow>
<mml:mo>&#x3d;</mml:mo>
<mml:mrow>
<mml:mfenced open="{" close="}" separators="|">
<mml:mrow>
<mml:mrow>
<mml:mfenced open="[" close="]" separators="|">
<mml:mrow>
<mml:mtext>total&#x2009;lesion&#x2009;volume</mml:mtext>
<mml:mo>&#x2010;</mml:mo>
<mml:mrow>
<mml:mfenced open="(" close=")" separators="|">
<mml:mrow>
<mml:mtext>left&#x2009;hemisphere&#x2009;volume</mml:mtext>
<mml:mo>&#x2010;</mml:mo>
<mml:mtext>right&#x2009;hemisphere&#x2009;volume</mml:mtext>
</mml:mrow>
</mml:mfenced>
</mml:mrow>
</mml:mrow>
</mml:mfenced>
</mml:mrow>
<mml:mrow>
<mml:mo>/</mml:mo>
</mml:mrow>
<mml:mtext>right&#x2009;hemisphere&#x2009;volume</mml:mtext>
</mml:mrow>
</mml:mfenced>
</mml:mrow>
<mml:mo>&#xd7;</mml:mo>
<mml:mn>100</mml:mn>
<mml:mo>%</mml:mo>
</mml:mrow>
</mml:math>
</disp-formula>
</p>
</sec>
<sec id="s2-5-4">
<title>2.5.4 Hematoxylin and Eosin staining</title>
<p>The brain tissue was soaked in 4% paraformaldehyde solution overnight, dehydrated, embedded in paraffin, then sliced by an ultrathin microtome with a thickness of 5&#x2013;8&#xa0;&#x3bc;m, dried and stained with Hematoxylin and Eosin staining (HE), and observed under the microscope.</p>
</sec>
<sec id="s2-5-5">
<title>2.5.5 ELISA was used to detect serum levels of IL-4, IL-6, TNF-&#x3b1;, and MMP-9</title>
<p>Rat abdominal aorta blood was collected, left at room temperature for 30&#xa0;min, then placed in a 4&#xb0;C centrifuge, and centrifuged at 3,000&#xa0;r/min for 10&#xa0;min. The upper serum layer was retrieved according to the kit requirements to determine the content of relevant indicators.</p>
</sec>
<sec id="s2-5-6">
<title>2.5.6 Immunohistochemistry for the expression of the claudin-5, CD86 (M1), and CD206 (M2) protein in the cerebral cortex</title>
<p>After embedding in paraffin, brain tissue was cut and immunohistochemical staining was performed. Monoclonal antibodies for claudin-5, CD86, and CD206 were diluted 1:500, respectively. The distribution of target protein was observed under the microscope and the brown particles showed positive expression. ImageJ software measured the optical density (OD) values of brown particles on each wall of the wall of the blood vessel under each visual field and calculated the average value, representing the expression of the corresponding protein.</p>
</sec>
<sec id="s2-5-7">
<title>2.5.7 Immunofluorescence detected CCR2<sup>&#x2b;</sup>/CD68<sup>&#x2b;</sup> macrophages</title>
<p>Paraffin specimens of brain tissue were prepared and sectioned. The sections were blocked in 3% hydrogen peroxide at room temperature for 30 min, and then rinsed in distilled water for 3 min. After sealing with 10% goat serum, take 1 &#x03BC;L of the original solutions of CCR2 and CD68 antibodies, prepare the working antibody solution, add the primary antibody, and incubate at 4&#x00B0;C overnight. The next day, the slices were rinsed with TBST, soaked several times, added with secondary antibody, incubated and removed from the oven. After removing TBST, each section was exposed to 50&#xa0;&#x3bc;L DAPI, incubated in the dark, and rinsed with TBST. The slides were sealed with fluorescent sealer and examined under the microscope and then stored away from light. Pathological changes were observed by fluorescence microscopy. Immunofluorescence staining was quantified using ImageJ.</p>
</sec>
<sec id="s2-5-8">
<title>2.5.8 Western blotting detected the expression of the CCL2 and CCR2 proteins in brain tissue</title>
<p>Brain tissue was lysed on ice for 40&#xa0;min, centrifuged, and protein was extracted and Western blotting followed the procedure outlined in <xref ref-type="sec" rid="s2-4-8">Section 2.4.8</xref>.</p>
</sec>
<sec id="s2-5-9">
<title>2.5.9 RT-qPCR detection of CCL2 and CCR2 protein expression in brain tissue</title>
<p>Brain tissue was used to prepare a homogenate. RT-PCR was performed as described in <xref ref-type="sec" rid="s2-4-9">Section 2.4.9</xref>.</p>
</sec>
</sec>
<sec id="s2-6">
<title>2.6 Statistical analysis</title>
<p>The experimental data were statistically analyzed and plotted using GraphPadPrism v.8.0.2 software, and the results were expressed as x &#xb1; s. The independent <italic>t</italic>-test was used for comparison between the two groups. <italic>p</italic> &#x3c; 0.05 was considered statistically significant.</p>
</sec>
</sec>
<sec sec-type="results" id="s3">
<title>3 Results</title>
<sec id="s3-1">
<title>3.1 Potential immunoinflammatory-related targets of THSWD in the treatment of ischemic stroke</title>
<sec id="s3-1-1">
<title>3.1.1 Differential gene expression and GSEA analysis following THSWD treatment for ischemic stroke</title>
<p>DEG screening for DVSM and MVSC was performed using R.4.2.1, A <italic>P</italic>-value &#x3c;0.05 and the absolute value of logFC &#x3e;1 were set as intermediate values. In total, 806 upregulated genes and 226 downregulated genes were detected following MVSC treatment (<xref ref-type="fig" rid="F1">Figure 1A</xref>), and 401 downregulated genes and 114 upregulated genes were identified for DVSM, for a total of 515 DEGs. Of these, THSWD downregulated 285 genes and upregulated 61 genes (<xref ref-type="fig" rid="F1">Figure 1B</xref>). The expression profile of the comparison group DVSM and MVSC was analyzed by GSEA, <italic>P</italic>-valueCutoff &#x3d; 0.05. MVSC activated 24 immune-related pathways (<xref ref-type="fig" rid="F1">Figure 1C</xref>) and DVSM activated 12 immune-related pathways (<xref ref-type="fig" rid="F1">Figure 1D</xref>) and immunoinflammatory pathways were significantly enriched.</p>
<fig id="F1" position="float">
<label>FIGURE 1</label>
<caption>
<p>Differential gene screening and GSEA analysis of THSWD treatment for ischemic stroke. <bold>(A)</bold> MVSC volcano map, <bold>(B)</bold> DVSM volcano map, <bold>(C, D)</bold> Gene set enrichment analysis of mRNA transcriptome sequencing data.</p>
</caption>
<graphic xlink:href="fphar-15-1428572-g001.tif"/>
</fig>
</sec>
<sec id="s3-1-2">
<title>3.1.2 Screening and enrichment analysis of immunoinflammatory genes following treatment with THSWD for ischemic stroke</title>
<p>There were 92 immunoinflammatory-related differential genes in the THSWD intervention for stroke (<xref ref-type="fig" rid="F2">Figure 2A</xref>). The GO enrichment analysis of immunoinflammation-related differential genes is shown in <xref ref-type="fig" rid="F2">Figure 2B</xref> and the KEGG enrichment analysis is shown in <xref ref-type="fig" rid="F2">Figure 2C</xref>.</p>
<fig id="F2" position="float">
<label>FIGURE 2</label>
<caption>
<p>
<bold>(A)</bold> Immune inflammation-related gene screening <bold>(B)</bold> Immunoinflammatory-related differential gene GO enrichment analysis (Top25). <bold>(C)</bold> Immunoinflammatory-related differential gene KEGG analysis (Top25).</p>
</caption>
<graphic xlink:href="fphar-15-1428572-g002.tif"/>
</fig>
</sec>
<sec id="s3-1-3">
<title>3.1.3 PPI network construction and screening of key genes</title>
<p>String (<ext-link ext-link-type="uri" xlink:href="https://cn.string-db.org/">https://cn.string-db.org/</ext-link>) was used to construct a PPI network map of 92 immunoinflammatory genes, which was imported into Cytoscape v.3.9.1 to visualize the selected genes with the MCC algorithm. The five genes with the highest scores (<italic>Cd68, Ccl2, Mmp9, Lgals3, Cd44</italic>) were identified as key genes (<xref ref-type="fig" rid="F3">Figure 3</xref>).</p>
<fig id="F3" position="float">
<label>FIGURE 3</label>
<caption>
<p>HUB gene screening.</p>
</caption>
<graphic xlink:href="fphar-15-1428572-g003.tif"/>
</fig>
</sec>
</sec>
<sec id="s3-2">
<title>3.2 THSWD alleviated OGD/R-induced HBMEC damage by inhibiting the CCL2/CCR2 axis</title>
<sec id="s3-2-1">
<title>3.2.1 Inhibition of the CCL2/CCR2 axis protected HBMEC cells from OGD/R-induced damage</title>
<p>The results of the CCK-8 assay found that the strongest cell proliferation effect was observed in the drug-containing serum containing the 10% concentration and 48&#xa0;h after administration, which was then selected as the conditions for subsequent experiments (<xref ref-type="fig" rid="F4">Figure 4A</xref>). CCL2/CCR2 axis inhibitors antagonized OGD/R-induced HBMEC damage, and decreased cell activity was observed following exposure to OGD/R. CCR2 inhibitors increased cell viability (<italic>p</italic> &#x3c; 0.01), whereas CCL2/CCR2 axis agonists induced the opposite effect (<italic>p</italic> &#x3c; 0.01) (<xref ref-type="fig" rid="F4">Figure 4B</xref>). The permeability of HBMEC was detected by FITC-dextran. OGD/R injury significantly improved the permeability of HBMEC cells (<italic>p</italic> &#x3c; 0.01), whereas the CCL2/CCR2 axis inhibitor significantly reversed this increase (<italic>p</italic> &#x3c; 0.01) (<xref ref-type="fig" rid="F4">Figure 4C</xref>). The expression of claudin-5 following OGD/R injury was reduced compared to the control group (<italic>p</italic> &#x3c; 0.01), indicating that HBMEC was damaged, which was reversed by treatment with CCL2/CCR2 axis inhibitors (<italic>p</italic> &#x3c; 0.01), indicating that CCL2/CCR2 axis inhibitors maintained endothelial cell function (<xref ref-type="fig" rid="F4">Figure 4D</xref>).</p>
<fig id="F4" position="float">
<label>FIGURE 4</label>
<caption>
<p>Inhibition of the CCL2/CCR2 axis can attenuate OGD/R damage in HBMEC. <bold>(A)</bold> Screening of drug-containing serum. <bold>(B)</bold> Effect of the CCL2/CCR2 axis on HBMEC activity. <bold>(C)</bold> FITC permeability of HBMEC. <bold>(D)</bold> Effect of the CCL2/CCR2 axis on claudin-5. <sup>&#x23;&#x23;</sup>
<italic>P</italic> &#x3c; 0.01 vs. control; <sup>&#x2a;&#x2a;</sup>
<italic>p</italic> &#x3c; 0.01 vs. OGD/R.</p>
</caption>
<graphic xlink:href="fphar-15-1428572-g004.tif"/>
</fig>
</sec>
<sec id="s3-2-2">
<title>3.2.2 Inhibition of the CCL2/CCR2 axis reduced macrophage polarization and the release of inflammatory factors</title>
<p>Flow cytometry was used to detect macrophage polarization, and it was found that the CCL2/CCR2 axis inhibitors reduced M1/M2 (<italic>P</italic>&#x3c;0.01), indicating that the CCL2/CCR2 axis inhibitors caused macrophages to switch from the pro-inflammatory subgroup (M1) to the anti-inflammatory subgroup (M2) (<xref ref-type="fig" rid="F5">Figure 5A</xref>). ELISA was used to evaluate the release of inflammatory cytokines in all experimental groups. The expression of pro-inflammatory cytokines IL-6, MMP-9, and TNF-&#x430; were decreased in the CCL2/CCR2 axis inhibitor group (<italic>p</italic> &#x3c; 0.01). In contrast, the expression of anti-inflammatory factor IL-4 was significantly increased (<italic>p</italic> &#x3c; 0.01) (<xref ref-type="fig" rid="F5">Figure 5B</xref>).</p>
<fig id="F5" position="float">
<label>FIGURE 5</label>
<caption>
<p>Inhibition of the CCL2/CCR2 axis can reduce macrophage polarization and inflammatory factor release. <bold>(A)</bold> Macrophage polarization. <bold>(B)</bold> Inflammatory factor. <sup>&#x23;&#x23;</sup>
<italic>p</italic> &#x3c; 0.01 vs. control; <sup>&#x2a;&#x2a;</sup>
<italic>p</italic> &#x3c; 0.01 vs. OGD/R.</p>
</caption>
<graphic xlink:href="fphar-15-1428572-g005.tif"/>
</fig>
</sec>
<sec id="s3-2-3">
<title>3.2.3 Expression of proteins and genes related to the CCL2/CCR2 axis</title>
<p>Western blotting showed that CCL2/CCR2 axis inhibitor significantly inhibited the expression of CCL2 and CCR2 compared with other groups (<italic>p</italic> &#x3c; 0.01, <italic>p</italic> &#x3c; 0.05) (<xref ref-type="fig" rid="F6">Figure 6A</xref>), and RT-qPCR indicated that CCL2 and CCR2 expression was downregulated in the CCL2/CCR2 axis inhibitor group (<italic>p</italic> &#x3c; 0.01) (<xref ref-type="fig" rid="F6">Figure 6B</xref>).</p>
<fig id="F6" position="float">
<label>FIGURE 6</label>
<caption>
<p>Expression of proteins and genes associated with the CCL2/CCR2 axis. <bold>(A)</bold> Western blotting; <bold>(B)</bold> RT-qPCR. <sup>&#x23;&#x23;</sup>
<italic>p</italic> &#x3c; 0.01 vs. control; <sup>&#x2a;</sup>
<italic>p</italic> &#x3c; 0.05, <sup>&#x2a;&#x2a;</sup>
<italic>p</italic> &#x3c; 0.01 vs. OGD/R.</p>
</caption>
<graphic xlink:href="fphar-15-1428572-g006.tif"/>
</fig>
</sec>
<sec id="s3-2-4">
<title>3.2.4 THSWD alleviated the damage to the OGD/R model of HBMEC</title>
<p>The FITC glucan assay showed that the THSWD group alleviated HBMEC permeability (<italic>p</italic> &#x3c; 0.01) and THSWD could reverse the increased permeability of HBMEC induced by CCL2/CCR2 axis agonists (<italic>p</italic> &#x3c; 0.05) (<xref ref-type="fig" rid="F7">Figure 7A</xref>). Furthermore, the immunofluorescence results revealed that claudin-5 expression was increased in the THSWD group (<italic>p</italic> &#x3c; 0.01), and that THSWD could reverse the damage to HBMEC caused by CCL2/CCR2 axis agonists (<italic>p</italic> &#x3c; 0.01) (<xref ref-type="fig" rid="F7">Figure 7B</xref>).</p>
<fig id="F7" position="float">
<label>FIGURE 7</label>
<caption>
<p>THSWD inhibition of the CCL2/CCR2 axis alleviates HBMEC cell injury. <bold>(A)</bold> FITC permeability of HBMEC. <bold>(B)</bold> THSWD inhibits the effect of the CCL2/CCR2 axis on claudin-5 expression. <sup>&#x23;</sup>
<italic>P</italic> &#x3c; 0.05, <sup>&#x23;&#x23;</sup>
<italic>P</italic> &#x3c; 0.01 vs. control; <sup>&#x2a;</sup>
<italic>p</italic> &#x3c; 0.05, <sup>&#x2a;&#x2a;</sup>
<italic>p</italic> &#x3c; 0.01 vs. OGD/R.</p>
</caption>
<graphic xlink:href="fphar-15-1428572-g007.tif"/>
</fig>
</sec>
<sec id="s3-2-5">
<title>3.2.5 THSWD inhibited macrophage polarization</title>
<p>After co-culture of endothelial cells and macrophages, flow cytometry showed that the proportion of macrophages M1 and M2 (M1/M2) in the THSWD group was reduced (<italic>p</italic> &#x3c; 0.01). THSWD also reversed macrophage-induced polarization in the CCL2/CCR2 axis agonist group (<italic>p</italic> &#x3c; 0.01) (<xref ref-type="fig" rid="F8">Figure 8</xref>).</p>
<fig id="F8" position="float">
<label>FIGURE 8</label>
<caption>
<p>THSWD inhibits the CCL2/CCR2 axis and inhibits macrophage polarization. <sup>&#x23;&#x23;</sup>
<italic>P</italic> &#x3c; 0.01 vs. control; <sup>&#x2a;&#x2a;</sup>
<italic>p</italic> &#x3c; 0.01 vs. OGD/R.</p>
</caption>
<graphic xlink:href="fphar-15-1428572-g008.tif"/>
</fig>
</sec>
</sec>
<sec id="s3-3">
<title>3.3 THSWD exerted a protective effect on MCAO/R rats by inhibiting the CCL2/CCR2 axis</title>
<sec id="s3-3-1">
<title>3.3.1 THSWD alleviated nerve function injury and blood-brain barrier injury in MCAO/R rats</title>
<p>Compared with the sham group, the neural function score of rats in the MCAO/R group was increased (<italic>p</italic> &#x3c; 0.01) (<xref ref-type="fig" rid="F9">Figure 9A</xref>); TTC staining showed infarction on the same side of the brain section (<italic>p</italic> &#x3c; 0.01) (<xref ref-type="fig" rid="F9">Figure 9B</xref>). HE staining revealed disordered neuronal cell arrangement, damaged cell structure, and atrophy of nucleus in the brain tissue of the MCAO/R group (<xref ref-type="fig" rid="F9">Figure 9C</xref>). Rats in the THSWD group and the NMDP group showed a decrease in the nerve function score (<italic>p</italic> &#x3c; 0.05), a decrease in the area of cerebral infarction area (<italic>p</italic> &#x3c; 0.05, <italic>p</italic> &#x3c; 0.01), and an improvement in HE-stained neurons damage, which was dose dependent. On immunohistochemistry, the expression of the claudin-5 protein in the MCAO/R group was lower than in the sham group (<italic>p</italic> &#x3c; 0.01), whereas the expression of the claudin-5 protein in the H-THSWD, M-THSWD, L-THSWD, and NMDP groups increased (<italic>p</italic> &#x3c; 0.05, <italic>p</italic> &#x3c; 0.01) (<xref ref-type="fig" rid="F9">Figure 9D</xref>).</p>
<fig id="F9" position="float">
<label>FIGURE 9</label>
<caption>
<p>
<bold>(A)</bold> THSWD decreased the neurological function score of MCAO/R rats (n &#x3d; 10); <bold>(B)</bold> TTC staining showed cerebral infarction volume (n &#x3d; 3); <bold>(C)</bold> neuronal damage (HE, &#xd7;400); <bold>(D)</bold> THSWD increased the expression of claudin-5 in MCAO/R rats. <sup>&#x23;</sup>
<italic>P</italic> &#x3c; 0.05, <sup>&#x23;&#x23;</sup>
<italic>P</italic> &#x3c; 0.01 vs. sham; <sup>&#x2a;</sup>
<italic>p</italic> &#x3c; 0.05, <sup>&#x2a;&#x2a;</sup>
<italic>p</italic> &#x3c; 0.01 vs. MCAO/R.</p>
</caption>
<graphic xlink:href="fphar-15-1428572-g009.tif"/>
</fig>
</sec>
<sec id="s3-3-2">
<title>3.3.2 THSWD inhibited infiltration and polarization of brain macrophages in MCAO/R rats</title>
<p>It is well known that chemokine-chemokine receptor interactions induce the recruitment of inflammatory cells, and our results showed that most inflammatory cells expressing CCR2 were CD68-positive cells, indicating that the CCL2/CCR2 axis was significantly correlated with increased macrophage recruitment. Compared to the sham group, the reaction intensity of CCR2<sup>&#x002B;</sup>/CD68<sup>&#x002B;</sup> cells in the MCAO/R group significantly increased (<italic>p</italic> &#x003C; 0.01), while this phenomenon was reversed in the H-THSWD, M-THSWD, and NMDP groups (<italic>p</italic> &#x003C; 0.05, <italic>p</italic> &#x003C; 0.01) (<xref ref-type="fig" rid="F10">Figure 10</xref>). Immunohistochemical identification of CD86 (M1) and CD206 (M2) macrophages showed that compared to the sham group, the number of M1 macrophages increased (<italic>p</italic> &#x3c; 0.05) and M2 macrophages decreased significantly (<italic>p</italic> &#x3c; 0.01) in the MCAO/R group (<xref ref-type="fig" rid="F11">Figures 11A, B</xref>). The H-THSWD, M-THSWD, L-THSWD, and NMDP groups all reversed the above phenomenon. (<italic>p</italic> &#x3c; 0.05, <italic>p</italic> &#x3c; 0.01).</p>
<fig id="F10" position="float">
<label>FIGURE 10</label>
<caption>
<p>The intensity of CCR2<sup>&#x2b;</sup>/CD68<sup>&#x2b;</sup>cell reaction; <sup>&#x23;&#x23;</sup>
<italic>P</italic> &#x3c; 0.01 vs. sham; <sup>&#x2a;</sup>
<italic>p</italic> &#x3c; 0.05, <sup>&#x2a;&#x2a;</sup>
<italic>p</italic> &#x3c; 0.01 vs. MCAO/R.</p>
</caption>
<graphic xlink:href="fphar-15-1428572-g010.tif"/>
</fig>
<fig id="F11" position="float">
<label>FIGURE 11</label>
<caption>
<p>Expression of CD86 (M1) and CD206 (M2). <bold>(A)</bold>: Expression of CD86 (M1); <bold>(B)</bold>: Expression of CD206 (M2). <sup>&#x23;</sup>
<italic>P</italic> &#x3c; 0.05, <sup>&#x23;&#x23;</sup>
<italic>P</italic> &#x3c; 0.01 vs. sham; <sup>&#x2a;</sup>
<italic>p</italic> &#x3c; 0.05, <sup>&#x2a;&#x2a;</sup>
<italic>p</italic> &#x3c; 0.01 vs. MCAO/R.</p>
</caption>
<graphic xlink:href="fphar-15-1428572-g011.tif"/>
</fig>
</sec>
<sec id="s3-3-3">
<title>3.3.3 THSWD inhibited the release of inflammatory factors and the expression of genes and proteins of the CCL2/CCR2 axis in the hippocampus of MCAO/R rats</title>
<p>The ELISA showed that the release of proinflammatory factors MMP-9, TNF-&#x3b1; and IL - 6 by the MCAO/R group were significantly higher than those of the sham group (<italic>p</italic> &#x3c; 0.01), IL-4 showed the opposite trend (<italic>p</italic> &#x3c; 0.01), whereas THSWD and NMDP treatment groups reversed the expression of inflammatory factors (<italic>p</italic> &#x3c; 0.05, <italic>p</italic> &#x3c; 0.01) (<xref ref-type="fig" rid="F12">Figure 12A</xref>); In addition, the gene and protein expression of CCL2 and CCR2 in the MCAO/R group was higher than that in the sham group (<italic>p</italic> &#x3c; 0.01) (<xref ref-type="fig" rid="F12">Figures 12B, C</xref>). Similarly, this phenomenon was reversed in the THSWD and NMDP groups (<italic>p</italic> &#x3c; 0.05, <italic>p</italic> &#x3c; 0.01).</p>
<fig id="F12" position="float">
<label>FIGURE 12</label>
<caption>
<p>THSWD inhibits the release of inflammatory factors and the CCL2/CCR2 axis. <bold>(A)</bold> Inflammatory cytokines. <bold>(B)</bold> Western blotting. <bold>(C)</bold> RT-qPCR. <sup>&#x23;</sup>
<italic>P</italic> &#x3c; 0.05, <sup>&#x23;&#x23;</sup>
<italic>P</italic> &#x3c; 0.01 vs. sham; <sup>&#x2a;</sup>
<italic>p</italic> &#x3c; 0.05, <sup>&#x2a;&#x2a;</sup>
<italic>p</italic> &#x3c; 0.01 vs. MCAO/R.</p>
</caption>
<graphic xlink:href="fphar-15-1428572-g012.tif"/>
</fig>
</sec>
</sec>
</sec>
<sec sec-type="discussion" id="s4">
<title>4 Discussion</title>
<p>Bioinformatics has been extensively used in the study of ischemic stroke. <xref ref-type="bibr" rid="B13">Li et al. (2020)</xref> using bioinformatics, found that the expression of CCL2 in the ischemic stroke group increased and promoted the progression of ischemic stroke by activating chemokine signaling and other pathways. In this study, through downstream analysis of transcriptome data from MCAO/R rats treated with THSWD, GSEA showed that gene sets were significantly enriched in the immunoinflammatory pathway and key genes such as Cd68 and Ccl2 were finally selected.</p>
<p>Macrophages are highly plastic, and when stimulated by the microenvironment, their polarization is triggered; they are usually divided into M1 and M2 types according to their cell function and metabolic pattern (<xref ref-type="bibr" rid="B8">Deng et al., 2023</xref>), M1 macrophages initiate pro-inflammatory responses, whereas M2 macrophages mediate anti-inflammatory processes. An imbalance in the M1-M2 polarization of macrophages is often associated with various diseases or inflammation (<xref ref-type="bibr" rid="B24">Wang et al., 2014</xref>). The phenotypic polarization of macrophages is usually studied by detecting M1-polarized macrophage markers CD86, CD16, and iNOS and M2-polarized macrophage markers CD206, Arg, and Ym1 (<xref ref-type="bibr" rid="B18">Spiller et al., 2014</xref>). BBB integrity is damaged after ischemic stroke (<xref ref-type="bibr" rid="B1">Ahmad et al., 2019</xref>). Natural immune cells are activated to migrate to the ischemic site in response to chemokines and pass through the damaged BBB (<xref ref-type="bibr" rid="B29">Zeng et al., 2022</xref>). Subsequently, macrophages in ischemic brain tissue are activated to further release inflammatory factors, exacerbating the chemotaxis of innate immune cells (<xref ref-type="bibr" rid="B5">Bayraktutan, 2019</xref>). Macrophages are one of the main drivers of inflammation during ischemia and stroke, and it has been shown that SP (undeceptide) is highly effective in the early control of ischemic stroke-induced inflammation. Possibly by recruiting M2 monocytes/macrophages into the injured brain, the M2 microglia/macrophages in the rat brain hemispheres after SP injection were significantly increased and inflammation was reduced. Thus, SP treatment significantly inhibited the destructive inflammatory response and protected and repaired the tissue microenvironment (<xref ref-type="bibr" rid="B2">Ahn et al., 2023</xref>). In this study, CD86 and CD206 were detected at the cellular and animal levels, respectively, and THSWD treatment resulted in a significant decrease in M1 macrophages and a significant increase in M2 macrophages compared with the model group. It indicated that THSWD could inhibit macrophage polarization.</p>
<p>CCR2 is a major macrophage chemokine receptor, and together with its ligand CCL2, plays an important role in neuroinflammation, mediating the recruitment of infiltrating macrophages and resident microglia to inflammatory sites in the central nervous system (<xref ref-type="bibr" rid="B6">Bianconi et al., 2018</xref>). Furthermore, downregulation of CCL2/CCR2 can inhibit macrophage infiltration and reduce microglial/macrophage M1 polarization (<xref ref-type="bibr" rid="B28">Yang et al., 2020</xref>). Meanwhile, CCL2 has a destructive effect on the BBB, which is directly mediated by the expression of CCR2 in endothelial cells (<xref ref-type="bibr" rid="B17">Skelly et al., 2013</xref>) After the CCR2 gene is knocked out, the effect of CCL2 on the permeability of the BBB is eliminated (<xref ref-type="bibr" rid="B11">Geng et al., 2022</xref>). In conclusion, inhibition of CCL2/CCR2 can reduce cerebral ischemic injury through multiple mechanisms (<xref ref-type="bibr" rid="B19">Stowe et al., 2012</xref>; <xref ref-type="bibr" rid="B27">Xu et al., 2022</xref>). In this study, we found that inhibition of the CCL2/CCR2 axis led to a reduction in macrophage polarization and a decrease in the permeability of HBMEC. Conversely, activation of the CCL2/CCR2 axis resulted in opposite effects. Furthermore, THSWD significantly suppressed the release of inflammatory cytokines and the expression of CCL2/CCR2 axis genes and proteins in the hippocampus of MCAO/R rats. Additionally, THSWD was able to reverse the damage to HBMEC and the polarization of macrophages caused by an agonist of the CCL2/CCR2 axis. This indicates that THSWD can antagonize the effects induced by CCL2/CCR2 axis agonists, thereby inhibiting the polarization of M1 macrophages, reducing inflammatory damage, and protecting the BBB (<xref ref-type="fig" rid="F13">Figure 13</xref>).</p>
<fig id="F13" position="float">
<label>FIGURE 13</label>
<caption>
<p>Mechanisms of CCL2/CCR2 axis in ischemic stroke and intervention of THSWD.</p>
</caption>
<graphic xlink:href="fphar-15-1428572-g013.tif"/>
</fig>
<p>As previously mentioned, this study used bioinformatics to screen genes related to the immune inflammation of ischemic stroke treated with THSWD, conducted an in-depth study of the potential mechanisms by which THSWD regulates the CCL2/CCR2 axis, and provided a theoretical basis for the preclinical research of THSWD in the treatment of ischemic stroke. However, there are still areas that can be improved: 1) Conduct gene knockout studies on CCL2 to verify its impact on ischemic stroke and the effects of THSWD; 2) Carry out in-depth studies on other immune-inflammatory related genes (Mmp9, Lgals3, Cd44) identified through bioinformatics.</p>
</sec>
<sec sec-type="conclusion" id="s5">
<title>5 Conclusion</title>
<p>The CCL2/CCR2 axis is involved in the occurrence and development of ischemic stroke and may play a protective role against ischemic stroke injury in rats by reducing macrophage infiltration and inhibiting macrophage polarization of the M1 type, thus reducing inflammatory damage and protecting the blood-brain barrier. THSWD may play a protective role in inflammation after ischemic stroke by regulating the CCL2/CCR2 axis.</p>
</sec>
</body>
<back>
<sec sec-type="data-availability" id="s6">
<title>Data availability statement</title>
<p>The original contributions presented in the study are included in the article/supplementary material, further inquiries can be directed to the corresponding authors.</p>
</sec>
<sec id="s7">
<title>Ethics statement</title>
<p>The animal study was approved by Experimental Animal Ethics Committee of Anhui University of Chinese Medicine. The study was conducted in accordance with the local legislation and institutional requirements.</p>
</sec>
<sec id="s8">
<title>Author contributions</title>
<p>JL: Conceptualization, Investigation, Writing&#x2013;original draft. LZ: Conceptualization, Investigation, Writing&#x2013;original draft. SX: Data curation, Writing&#x2013;review and editing. CY: Formal Analysis, Investigation, Writing&#x2013;review and editing. YL: Formal Analysis, Writing&#x2013;review and editing. SL: Investigation, Resources, Writing&#x2013;review and editing. QY: Investigation, Resources, Writing&#x2013;review and editing. XD: Funding acquisition, Supervision, Writing&#x2013;review and editing. DP: Supervision, Writing&#x2013;review and editing.</p>
</sec>
<sec sec-type="funding-information" id="s9">
<title>Funding</title>
<p>The author(s) declare that financial support was received for the research, authorship, and/or publication of this article. This research was supported by the National Natural Science Foundation of China (Reference: 82074059), the Anhui Provincial Hygiene and Health Outstanding Talents Project (Reference: ahsjhmypygc20230074), the Anhui Provincial Health Research Key Project (Reference: AHWJ2022a013), the Anhui Province Academic Leader Reserve Candidate Funding Project (Reference: 2022H287), the Open Fund for Key Laboratory of Xin&#x2019;an Medical Ministry of Education, Anhui University of Traditional Chinese Medicine (Reference: 2022XAYX07), and Anhui Province University Scientific Research Project (No. 2023AH050745).</p>
</sec>
<ack>
<p>We thank everyone for their contributions to this research.</p>
</ack>
<sec sec-type="COI-statement" id="s10">
<title>Conflict of interest</title>
<p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
</sec>
<sec sec-type="disclaimer" id="s11">
<title>Publisher&#x2019;s note</title>
<p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p>
</sec>
<ref-list>
<title>References</title>
<ref id="B1">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ahmad</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Khan</surname>
<given-names>S. A.</given-names>
</name>
<name>
<surname>Kindelin</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Mohseni</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Bhatia</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Hoda</surname>
<given-names>M. N.</given-names>
</name>
<etal/>
</person-group> (<year>2019</year>). <article-title>Acetyl-11-keto-&#x3b2;-boswellic acid (AKBA) attenuates oxidative stress, inflammation, complement activation and cell death in brain endothelial cells following OGD/reperfusion</article-title>. <source>Neuromolecular Med.</source> <volume>21</volume> (<issue>4</issue>), <fpage>505</fpage>&#x2013;<lpage>516</lpage>. <pub-id pub-id-type="doi">10.1007/s12017-019-08569-z</pub-id>
</citation>
</ref>
<ref id="B2">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ahn</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Chi</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Son</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>M.</given-names>
</name>
</person-group> (<year>2023</year>). <article-title>Substance P reduces infarct size and mortality after ischemic stroke, possibly through the M2 polarization of microglia/macrophages and neuroprotection in the ischemic rat brain</article-title>. <source>Cell. Mol. Neurobiol.</source> <volume>43</volume> (<issue>5</issue>), <fpage>2035</fpage>&#x2013;<lpage>2052</lpage>. <pub-id pub-id-type="doi">10.1007/s10571-022-01284-7</pub-id>
</citation>
</ref>
<ref id="B3">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bai</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Sun</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Cao</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Feng</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>J.</given-names>
</name>
</person-group> (<year>2023a</year>). <article-title>Monocyte-related cytokines/chemokines in cerebral ischemic stroke</article-title>. <source>CNS Neurosci. and Ther.</source> <volume>29</volume> (<issue>12</issue>), <fpage>3693</fpage>&#x2013;<lpage>3712</lpage>. <pub-id pub-id-type="doi">10.1111/cns.14368</pub-id>
</citation>
</ref>
<ref id="B4">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bai</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Sun</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Cao</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Feng</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>J.</given-names>
</name>
</person-group> (<year>2023b</year>). <article-title>Monocyte-related cytokines/chemokines in cerebral ischemic stroke</article-title>. <source>CNS Neurosci. Ther.</source> <volume>29</volume> (<issue>12</issue>), <fpage>3693</fpage>&#x2013;<lpage>3712</lpage>. <pub-id pub-id-type="doi">10.1111/cns.14368</pub-id>
</citation>
</ref>
<ref id="B5">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bayraktutan</surname>
<given-names>U.</given-names>
</name>
</person-group> (<year>2019</year>). <article-title>Endothelial progenitor cells: potential novel therapeutics for ischaemic stroke</article-title>. <source>Pharmacol. Res.</source> <volume>144</volume>, <fpage>181</fpage>&#x2013;<lpage>191</lpage>. <pub-id pub-id-type="doi">10.1016/j.phrs.2019.04.017</pub-id>
</citation>
</ref>
<ref id="B6">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bianconi</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Sahebkar</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Atkin</surname>
<given-names>S. L.</given-names>
</name>
<name>
<surname>Pirro</surname>
<given-names>M.</given-names>
</name>
</person-group> (<year>2018</year>). <article-title>The regulation and importance of monocyte chemoattractant protein-1</article-title>. <source>Curr. Opin. Hematol.</source> <volume>25</volume> (<issue>1</issue>), <fpage>44</fpage>&#x2013;<lpage>51</lpage>. <pub-id pub-id-type="doi">10.1097/MOH.0000000000000389</pub-id>
</citation>
</ref>
<ref id="B7">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cao</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Long</surname>
<given-names>J.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>Agomelatine prevents macrophage infiltration and brain endothelial cell damage in a stroke mouse model</article-title>. <source>Aging</source> <volume>13</volume> (<issue>10</issue>), <fpage>13548</fpage>&#x2013;<lpage>13559</lpage>. <pub-id pub-id-type="doi">10.18632/aging.202836</pub-id>
</citation>
</ref>
<ref id="B8">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Deng</surname>
<given-names>J.-Y.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>X.-Q.</given-names>
</name>
<name>
<surname>He</surname>
<given-names>W.-J.</given-names>
</name>
<name>
<surname>Liao</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Tang</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Nie</surname>
<given-names>X.-Q.</given-names>
</name>
</person-group> (<year>2023</year>). <article-title>Targeting DNA methylation and demethylation in diabetic foot ulcers</article-title>. <source>J. Adv. Res.</source> <volume>54</volume>, <fpage>119</fpage>&#x2013;<lpage>131</lpage>. <pub-id pub-id-type="doi">10.1016/j.jare.2023.01.009</pub-id>
</citation>
</ref>
<ref id="B9">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Duan</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Han</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Peng</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Peng</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Xiao</surname>
<given-names>L.</given-names>
</name>
<etal/>
</person-group> (<year>2018</year>). <article-title>High throughput mRNA sequencing reveals potential therapeutic targets of tao-hong-Si-Wu decoction in experimental middle cerebral artery occlusion</article-title>. <source>Front. Pharmacol.</source> <volume>9</volume>, <fpage>1570</fpage>. <pub-id pub-id-type="doi">10.3389/fphar.2018.01570</pub-id>
</citation>
</ref>
<ref id="B10">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Errede</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Annese</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Petrosino</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Longo</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Girolamo</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>de Trizio</surname>
<given-names>I.</given-names>
</name>
<etal/>
</person-group> (<year>2022</year>). <article-title>Microglia-derived CCL2 has a prime role in neocortex neuroinflammation</article-title>. <source>Fluids Barriers CNS</source> <volume>19</volume> (<issue>1</issue>), <fpage>68</fpage>. <pub-id pub-id-type="doi">10.1186/s12987-022-00365-5</pub-id>
</citation>
</ref>
<ref id="B11">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Geng</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Tang</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>Y. a.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>L.</given-names>
</name>
</person-group> (<year>2022</year>). <article-title>The role of CCL2/CCR2 Axis in cerebral ischemia-reperfusion injury and treatment: from animal experiments to clinical trials</article-title>. <source>Int. J. Mol. Sci.</source> <volume>23</volume> (<issue>7</issue>), <fpage>3485</fpage>. <pub-id pub-id-type="doi">10.3390/ijms23073485</pub-id>
</citation>
</ref>
<ref id="B12">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ji</surname>
<given-names>Z.-J.</given-names>
</name>
<name>
<surname>Shi</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Hou</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>Z.-Q.</given-names>
</name>
<etal/>
</person-group> (<year>2022</year>). <article-title>Neuroprotective effect of Taohong Siwu decoction on cerebral ischemia/reperfusion injury via mitophagy-NLRP3 inflammasome pathway</article-title>. <source>Front. Pharmacol.</source> <volume>13</volume>, <fpage>910217</fpage>. <pub-id pub-id-type="doi">10.3389/fphar.2022.910217</pub-id>
</citation>
</ref>
<ref id="B13">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Lou</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Zhu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>X. a.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>Upregulated C-C motif chemokine ligand 2 promotes ischemic stroke via chemokine signaling pathway</article-title>. <source>Ann. Vasc. Surg.</source> <volume>68</volume>, <fpage>476</fpage>&#x2013;<lpage>486</lpage>. <pub-id pub-id-type="doi">10.1016/j.avsg.2020.04.047</pub-id>
</citation>
</ref>
<ref id="B14">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Payen</surname>
<given-names>J. F.</given-names>
</name>
<name>
<surname>Fauvage</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Falcon</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Lavagne</surname>
<given-names>P.</given-names>
</name>
</person-group> (<year>2003</year>). <article-title>Brain oedema following blood-brain barrier disruption: mechanisms and diagnosis</article-title>. <source>Ann. Francaises D&#x27;anesthesie de Reanim.</source> <volume>22</volume> (<issue>3</issue>), <fpage>220</fpage>&#x2013;<lpage>225</lpage>. <pub-id pub-id-type="doi">10.1016/s0750-7658(03)00010-8</pub-id>
</citation>
</ref>
<ref id="B15">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Salvador</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Burek</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>F&#xf6;rster</surname>
<given-names>C. Y.</given-names>
</name>
</person-group> (<year>2015</year>). <article-title>Stretch and/or oxygen glucose deprivation (OGD) in an <italic>in vitro</italic> traumatic brain injury (TBI) model induces calcium alteration and inflammatory cascade</article-title>. <source>Front. Cell. Neurosci.</source> <volume>9</volume>, <fpage>323</fpage>. <pub-id pub-id-type="doi">10.3389/fncel.2015.00323</pub-id>
</citation>
</ref>
<ref id="B16">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shao</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>Y.-L.</given-names>
</name>
<name>
<surname>Du</surname>
<given-names>L.-J.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Zhu</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>L.-J.</given-names>
</name>
<etal/>
</person-group> (<year>2022</year>). <article-title>Macrophage nuclear receptor corepressor 1 deficiency protects against ischemic stroke in mice</article-title>. <source>J. Cardiovasc. Transl. Res.</source> <volume>15</volume> (<issue>4</issue>), <fpage>816</fpage>&#x2013;<lpage>827</lpage>. <pub-id pub-id-type="doi">10.1007/s12265-021-10187-9</pub-id>
</citation>
</ref>
<ref id="B17">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Skelly</surname>
<given-names>D. T.</given-names>
</name>
<name>
<surname>Hennessy</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Dansereau</surname>
<given-names>M.-A.</given-names>
</name>
<name>
<surname>Cunningham</surname>
<given-names>C.</given-names>
</name>
</person-group> (<year>2013</year>). <article-title>A systematic analysis of the peripheral and CNS effects of systemic LPS, IL-1&#x3b2;, [corrected] TNF-&#x3b1; and IL-6 challenges in C57BL/6 mice</article-title>. <source>PloS One</source> <volume>8</volume> (<issue>7</issue>), <fpage>e69123</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0069123</pub-id>
</citation>
</ref>
<ref id="B18">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Spiller</surname>
<given-names>K. L.</given-names>
</name>
<name>
<surname>Anfang</surname>
<given-names>R. R.</given-names>
</name>
<name>
<surname>Spiller</surname>
<given-names>K. J.</given-names>
</name>
<name>
<surname>Ng</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Nakazawa</surname>
<given-names>K. R.</given-names>
</name>
<name>
<surname>Daulton</surname>
<given-names>J. W.</given-names>
</name>
<etal/>
</person-group> (<year>2014</year>). <article-title>The role of macrophage phenotype in vascularization of tissue engineering scaffolds</article-title>. <source>Biomaterials</source> <volume>35</volume> (<issue>15</issue>), <fpage>4477</fpage>&#x2013;<lpage>4488</lpage>. <pub-id pub-id-type="doi">10.1016/j.biomaterials.2014.02.012</pub-id>
</citation>
</ref>
<ref id="B19">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Stowe</surname>
<given-names>A. M.</given-names>
</name>
<name>
<surname>Wacker</surname>
<given-names>B. K.</given-names>
</name>
<name>
<surname>Cravens</surname>
<given-names>P. D.</given-names>
</name>
<name>
<surname>Perfater</surname>
<given-names>J. L.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>M. K.</given-names>
</name>
<name>
<surname>Hu</surname>
<given-names>R.</given-names>
</name>
<etal/>
</person-group> (<year>2012</year>). <article-title>CCL2 upregulation triggers hypoxic preconditioning-induced protection from stroke</article-title>. <source>J. Neuroinflammation</source> <volume>9</volume>, <fpage>33</fpage>. <pub-id pub-id-type="doi">10.1186/1742-2094-9-33</pub-id>
</citation>
</ref>
<ref id="B20">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sun</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Fu</surname>
<given-names>F.</given-names>
</name>
</person-group> (<year>2023</year>). <article-title>The effect of triple reuptake inhibitor toludesvenlafaxine on neurological function in cerebral ischemic rats</article-title>. <source>Front. Pharmacol.</source> <volume>14</volume>, <fpage>1073099</fpage>. <pub-id pub-id-type="doi">10.3389/fphar.2023.1073099</pub-id>
</citation>
</ref>
<ref id="B21">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tang</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Chang</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Feng</surname>
<given-names>X.</given-names>
</name>
<etal/>
</person-group> (<year>2024</year>). <article-title>Treating ischemic stroke by improving vascular structure and promoting angiogenesis using Taohong Siwu Decoction: an integrative pharmacology strategy</article-title>. <source>J. Ethnopharmacol.</source> <volume>332</volume>, <fpage>118372</fpage>. <pub-id pub-id-type="doi">10.1016/j.jep.2024.118372</pub-id>
</citation>
</ref>
<ref id="B22">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Hu</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Duan</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Peng</surname>
<given-names>C.</given-names>
</name>
<etal/>
</person-group> (<year>2020</year>). <article-title>Taohong Siwu decoction ameliorates ischemic stroke injury via suppressing pyroptosis</article-title>. <source>Front. Pharmacol.</source> <volume>11</volume>, <fpage>590453</fpage>. <pub-id pub-id-type="doi">10.3389/fphar.2020.590453</pub-id>
</citation>
</ref>
<ref id="B23">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Fei</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Chu</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Pan</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Peng</surname>
<given-names>D.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>Taohong Siwu decoction regulates cell necrosis and neuroinflammation in the rat middle cerebral artery occlusion model</article-title>. <source>Front. Pharmacol.</source> <volume>12</volume>, <fpage>732358</fpage>. <pub-id pub-id-type="doi">10.3389/fphar.2021.732358</pub-id>
</citation>
</ref>
<ref id="B24">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Liang</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Zen</surname>
<given-names>K.</given-names>
</name>
</person-group> (<year>2014</year>). <article-title>Molecular mechanisms that influence the macrophage m1-m2 polarization balance</article-title>. <source>Front. Immunol.</source> <volume>5</volume>, <fpage>614</fpage>. <pub-id pub-id-type="doi">10.3389/fimmu.2014.00614</pub-id>
</citation>
</ref>
<ref id="B25">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Hu</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Zheng</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>J.</given-names>
</name>
<etal/>
</person-group> (<year>2022</year>). <article-title>The impact of potentially modifiable risk factors for stroke in a middle-income area of China: a case-control study</article-title>. <source>Front. Public Health</source> <volume>10</volume>, <fpage>815579</fpage>. <pub-id pub-id-type="doi">10.3389/fpubh.2022.815579</pub-id>
</citation>
</ref>
<ref id="B26">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Xie</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>S.</given-names>
</name>
</person-group> (<year>2022</year>). <article-title>Dihydromyricetin attenuates cerebral ischemia reperfusion injury by inhibiting SPHK1/mTOR signaling and targeting ferroptosis</article-title>. <source>Drug Des. Devel Ther.</source> <volume>16</volume>, <fpage>3071</fpage>&#x2013;<lpage>3085</lpage>. <pub-id pub-id-type="doi">10.2147/dddt.S378786</pub-id>
</citation>
</ref>
<ref id="B27">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Xu</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Ma</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Ji</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Shao</surname>
<given-names>Q.</given-names>
</name>
<etal/>
</person-group> (<year>2022</year>). <article-title>Identification of potential regulating effect of baicalin on NF&#x3ba;B/CCL2/CCR2 signaling pathway in rats with cerebral ischemia by antibody-based array and bioinformatics analysis</article-title>. <source>J. Ethnopharmacol.</source> <volume>284</volume>, <fpage>114773</fpage>. <pub-id pub-id-type="doi">10.1016/j.jep.2021.114773</pub-id>
</citation>
</ref>
<ref id="B28">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yang</surname>
<given-names>H.-C.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Zheng</surname>
<given-names>H.-Q.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>L.-Y.</given-names>
</name>
<name>
<surname>Luo</surname>
<given-names>J.</given-names>
</name>
<etal/>
</person-group> (<year>2020</year>). <article-title>C-C chemokine receptor type 2-overexpressing exosomes alleviated experimental post-stroke cognitive impairment by enhancing microglia/macrophage M2 polarization</article-title>. <source>World J. Stem Cells</source> <volume>12</volume> (<issue>2</issue>), <fpage>152</fpage>&#x2013;<lpage>167</lpage>. <pub-id pub-id-type="doi">10.4252/wjsc.v12.i2.152</pub-id>
</citation>
</ref>
<ref id="B29">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zeng</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Bao</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Zhu</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Xiang</surname>
<given-names>W.</given-names>
</name>
<etal/>
</person-group> (<year>2022</year>). <article-title>The mechanism of microglia-mediated immune inflammation in ischemic stroke and the role of natural botanical components in regulating microglia: a review</article-title>. <source>Front. Immunol.</source> <volume>13</volume>, <fpage>1047550</fpage>. <pub-id pub-id-type="doi">10.3389/fimmu.2022.1047550</pub-id>
</citation>
</ref>
</ref-list>
</back>
</article>